Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Brain structural anomalies in borderline and avoidant personality disorder patients and their associations with disorder-specific symptoms.

Denny BT, Fan J, Liu X, Guerreri S, Mayson SJ, Rimsky L, McMaster A, Alexander H, New AS, Goodman M, Perez-Rodriguez M, Siever LJ, Koenigsberg HW.

J Affect Disord. 2016 Aug;200:266-74. doi: 10.1016/j.jad.2016.04.053. Epub 2016 Apr 27.

2.

Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.

Van Eygen V, Thys K, Van Hove C, Rimsky LT, De Meyer S, Aerssens J, Picchio G, Vingerhoets J.

J Med Virol. 2016 May;88(5):798-806. doi: 10.1002/jmv.24395. Epub 2015 Oct 5.

PMID:
26412111
3.

Elevated amygdala activity during reappraisal anticipation predicts anxiety in avoidant personality disorder.

Denny BT, Fan J, Liu X, Ochsner KN, Guerreri S, Mayson SJ, Rimsky L, McMaster A, New AS, Goodman M, Siever LJ, Koenigsberg HW.

J Affect Disord. 2015 Feb 1;172:1-7. doi: 10.1016/j.jad.2014.09.017. Epub 2014 Sep 28.

4.

White matter abnormalities in schizophrenia and schizotypal personality disorder.

Lener MS, Wong E, Tang CY, Byne W, Goldstein KE, Blair NJ, Haznedar MM, New AS, Chemerinski E, Chu KW, Rimsky LS, Siever LJ, Koenigsberg HW, Hazlett EA.

Schizophr Bull. 2015 Jan;41(1):300-10. doi: 10.1093/schbul/sbu093. Epub 2014 Jun 23.

5.

Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.

Picchio GR, Rimsky LT, Van Eygen V, Haddad M, Napolitano LA, Vingerhoets J.

Antivir Ther. 2014;19(8):819-23. doi: 10.3851/IMP2771. Epub 2014 Apr 4.

PMID:
24704709
6.

Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.

Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, Elion RA, Vanveggel S, Stevens M, Rimsky L, Thorpe D, Bosse M, White K, Zhong L, DeMorin J, Chuck SK.

AIDS Patient Care STDS. 2014 Apr;28(4):168-75. doi: 10.1089/apc.2013.0310. Epub 2014 Mar 24.

7.

The neural correlates of anomalous habituation to negative emotional pictures in borderline and avoidant personality disorder patients.

Koenigsberg HW, Denny BT, Fan J, Liu X, Guerreri S, Mayson SJ, Rimsky L, New AS, Goodman M, Siever LJ.

Am J Psychiatry. 2014 Jan;171(1):82-90. doi: 10.1176/appi.ajp.2013.13070852.

8.

Insula-amygdala functional connectivity is correlated with habituation to repeated negative images.

Denny BT, Fan J, Liu X, Guerreri S, Mayson SJ, Rimsky L, New AS, Siever LJ, Koenigsberg HW.

Soc Cogn Affect Neurosci. 2014 Nov;9(11):1660-7. doi: 10.1093/scan/nst160. Epub 2013 Oct 29.

9.

Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.

Molina JM, Clumeck N, Orkin C, Rimsky LT, Vanveggel S, Stevens M; ECHO and THRIVE Study Groups.

HIV Med. 2014 Jan;15(1):57-62. doi: 10.1111/hiv.12071. Epub 2013 Aug 28.

10.

96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.

Rimsky L, Van Eygen V, Hoogstoel A, Stevens M, Boven K, Picchio G, Vingerhoets J.

Antivir Ther. 2013;18(8):967-77. doi: 10.3851/IMP2636. Epub 2013 May 28.

PMID:
23714781
11.

Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.

Molina JM, Clumeck N, Redant K, Rimsky L, Vanveggel S, Stevens M; ECHO Study Group; THRIVE Study Group.

AIDS. 2013 Mar 27;27(6):889-97. doi: 10.1097/QAD.0b013e32835e1554.

PMID:
23276806
12.

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.

Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, Rhame F, Stellbrink HJ, Li T, Crauwels H, Rimsky L, Vanveggel S, Williams P, Boven K; ECHO, THRIVE study groups.

AIDS. 2013 Mar 27;27(6):939-50. doi: 10.1097/QAD.0b013e32835cee6e.

PMID:
23211772
13.

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.

Vingerhoets J, Rimsky L, Van Eygen V, Nijs S, Vanveggel S, Boven K, Picchio G.

Antivir Ther. 2013;18(2):253-6. doi: 10.3851/IMP2358. Epub 2012 Sep 6.

PMID:
22951490
14.

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.

Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H, Johnson MA, Saag M, Supparatpinyo K, Crauwels H, Lefebvre E, Rimsky LT, Vanveggel S, Williams P, Boven K; ECHO Study Group; THRIVE Study Group.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):33-42. doi: 10.1097/QAI.0b013e31824d006e.

PMID:
22343174
15.

Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.

Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, Boven K, Picchio G.

J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):39-46. doi: 10.1097/QAI.0b013e31823df4da.

PMID:
22067667
16.

The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.

Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, Svarovskaia E, Miller MD, White KL.

J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):47-54. doi: 10.1097/QAI.0b013e31823aca74.

PMID:
21997204
17.

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.

Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group.

AIDS Res Hum Retroviruses. 2012 May;28(5):437-46. doi: 10.1089/AID.2011.0050. Epub 2011 Oct 17.

PMID:
21902621
18.

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K; ECHO study group.

Lancet. 2011 Jul 16;378(9787):238-46. doi: 10.1016/S0140-6736(11)60936-7.

PMID:
21763936
19.

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K; THRIVE study group.

Lancet. 2011 Jul 16;378(9787):229-37. doi: 10.1016/S0140-6736(11)60983-5.

PMID:
21763935
20.

Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.

Vingerhoets J, Azijn H, Tambuyzer L, Dierynck I, De Meyer S, Rimsky L, Nijs S, De Smedt G, de Béthune MP, Picchio G.

AIDS Res Hum Retroviruses. 2010 Jun;26(6):621-4. doi: 10.1089/aid.2009.0239.

PMID:
20507207
21.

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT.

Antimicrob Agents Chemother. 2010 Feb;54(2):718-27. doi: 10.1128/AAC.00986-09. Epub 2009 Nov 23.

22.

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.

Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group.

AIDS. 2010 Jan 2;24(1):55-65. doi: 10.1097/QAD.0b013e32833032ed.

PMID:
19926964
23.

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.

Tambuyzer L, Azijn H, Rimsky LT, Vingerhoets J, Lecocq P, Kraus G, Picchio G, de Béthune MP.

Antivir Ther. 2009;14(1):103-9.

PMID:
19320243
24.

tSNP-based identification of allelic loss of gene expression in a patient with a balanced chromosomal rearrangement.

Guzauskas GF, Ukadike K, Rimsky L, Srivastava AK.

Genomics. 2007 Apr;89(4):562-5. Epub 2007 Jan 22.

25.

Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.

Feng JY, Myrick FT, Margot NA, Mulamba GB, Rimsky L, Borroto-Esoda K, Selmi B, Canard B.

Nucleosides Nucleotides Nucleic Acids. 2006;25(1):89-107.

PMID:
16440988
26.

Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection.

Jacquard AC, Nassal M, Pichoud C, Ren S, Schultz U, Guerret S, Chevallier M, Werle B, Peyrol S, Jamard C, Rimsky LT, Trepo C, Zoulim F.

Antimicrob Agents Chemother. 2004 Jul;48(7):2683-92.

27.

Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.

Seignères B, Martin P, Werle B, Schorr O, Jamard C, Rimsky L, Trépo C, Zoulim F.

Antimicrob Agents Chemother. 2003 Jun;47(6):1842-52.

28.
29.

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.

Girard M, Meignier B, Barré-Sinoussi F, Kieny MP, Matthews T, Muchmore E, Nara PL, Wei Q, Rimsky L, Weinhold K, et al.

J Virol. 1995 Oct;69(10):6239-48.

30.

Rex transregulation of human T-cell leukemia virus type II gene expression.

Kim JH, Kaufman PA, Hanly SM, Rimsky LT, Greene WC.

J Virol. 1991 Jan;65(1):405-14.

31.
32.

Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator.

Rimsky L, Dodon MD, Dixon EP, Greene WC.

Nature. 1989 Oct 5;341(6241):453-6.

PMID:
2677743
33.

Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements.

Hanly SM, Rimsky LT, Malim MH, Kim JH, Hauber J, Duc Dodon M, Le SY, Maizel JV, Cullen BR, Greene WC.

Genes Dev. 1989 Oct;3(10):1534-44.

34.

Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins.

Böhnlein E, Siekevitz M, Ballard DW, Lowenthal JW, Rimsky L, Bogérd H, Hoffman J, Wano Y, Franza BR, Greene WC.

J Virol. 1989 Apr;63(4):1578-86.

35.

Identification of interleukin 1 alpha produced by the 3B6 human EBV-B cell line.

Bertoglio J, Wollman E, Shaw A, Rimsky L, Fradelizi D.

Lymphokine Res. 1989 Spring;8(1):19-24.

PMID:
2541284
36.

Cloning and expression of a cDNA for human thioredoxin.

Wollman EE, d'Auriol L, Rimsky L, Shaw A, Jacquot JP, Wingfield P, Graber P, Dessarps F, Robin P, Galibert F, et al.

J Biol Chem. 1988 Oct 25;263(30):15506-12.

37.

Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein.

Rimsky L, Hauber J, Dukovich M, Malim MH, Langlois A, Cullen BR, Greene WC.

Nature. 1988 Oct 20;335(6192):738-40.

PMID:
3262832
38.

A novel protein from cloned human B-cell line displays IL-1 bioactivity.

Bertoglio J, Wollman E, Rimsky L, Fradelizi D, Shaw A.

J Immunol. 1988 Oct 15;141(8):2869-70. No abstract available.

PMID:
3262670
39.

B-cell-derived interleukin-1.

Wakasugi H, Bensimon C, Mahé Y, Busson P, Rimsky L, Fradelizi D, Bertoglio J, Tursz T.

Ann Inst Pasteur Immunol. 1987 Jul-Aug;138(4):599-603. No abstract available.

PMID:
2823850
40.

Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor.

Wakasugi H, Rimsky L, Mahe Y, Kamel AM, Fradelizi D, Tursz T, Bertoglio J.

Proc Natl Acad Sci U S A. 1987 Feb;84(3):804-8.

41.

B-cell line-derived interleukin 1 is cytotoxic for melanoma cells and promotes the proliferation of an astrocytoma cell line.

Bertoglio JH, Rimsky L, Kleinerman ES, Lachman LB.

Lymphokine Res. 1987 Spring;6(2):83-91.

PMID:
3495709
42.

Purification to homogeneity and NH2-terminal amino acid sequence of a novel interleukin 1 species derived from a human B cell line.

Rimsky L, Wakasugi H, Ferrara P, Robin P, Capdevielle J, Tursz T, Fradelizi D, Bertoglio J.

J Immunol. 1986 May 1;136(9):3304-10.

PMID:
3485686
44.

[Secretion of two different monokines. Effect of TPA and silica].

Rimsky L, Souvannavong V, Le Bouffant L, Adam A.

C R Seances Acad Sci III. 1983;296(7):329-34. French.

PMID:
6307493

Supplemental Content

Loading ...
Support Center